Madhukar Pai

For decades, India has under-invested in TB control, says Madhukar Pai

India has not delivered because of poor investment and weak implementation, says Pai.

Read More →

Tuberculosis innovations mean little if they cannot save lives

In a paper published in eLife, Madhukar Pai and Jennifer Furin summarized the uptake of new TB tools such as GeneXpert, bedaquiline and delamanid, and identified the main barriers to scale-up and patient access.

Read More →

Tracking TB vaccination policies and practices through space and time

The 2nd Edition of the BCG World Atlas provides user friendly, open access, and easy to access data on the current TB vaccine, and provides the clinician, researcher, and public health practitioner alike with resources and information necessary to interpret current and novel TB diagnostics and conduct fruitful research on novel vaccines.

Read More →

PLOS Tuberculosis Channel launched

The Channel features articles on all topics relevant to TB research and aims to showcase the most up-to-date research to assist various stakeholders in the fight against TB.

Read More →

Regardless of the WHO snafu, TB should be a priority in the global AMR response

On 27 February, the WHO published a list of antibiotic-resistant "priority pathogens." The first of its kind, this list is intended to promote research, discovery and development (R&D) of new antibiotics, as part of WHO’s efforts to address the threat of antimicrobial resistance (AMR) and respond to an urgent public health need.  The hope is that the list will catalyse governments to incentivize basic science and advanced R&D.

Read More →

In India, eliminating TB isn't just a health issue — it's an economic one

Last month, India’s finance minister announced the government’s plan to eliminate tuberculosis by 2025 during the unveiling of the country’s Union Budget for 2017-2018. This is a welcome move: While ridding people of the burden of any disease is a worthy goal by itself, TB elimination provides perhaps one of the strongest economic cases for public intervention.

Read More →

'Cascade of care' can help India plug gaps in TB treatment

Tuberculosis (TB) is the leading infectious cause of death globally. In 2015, WHO estimated that there were 10.4 million new TB cases worldwide. Six countries accounted for 60 per cent of the total burden, with India accounting for 27 per cent of the global cases. The WHO highlighted that about 4.3 million TB patients globally are "missed" by health systems annually and remain either untreated or unreported to national governments, which may undermine global efforts to combat TB. India alone has more than one million of these missing TB patients every year.

Read More →

What India needs to do to win the fight against TB

The way forward is to invest in TB control, take public health benefits – free drugs and testing – to the unknown number of privately-treated patients.

Read More →

Implementation failures are threatening our plans to end the TB epidemic

It is a matter of great tragedy that tuberculosis (TB), despite being a curable infectious disease, continues to kill over 1.5 million people every year. Nearly 9.5 million new cases of TB occur worldwide every year. Of these, nearly 3 million TB patients are considered "missing" -- they are either not diagnosed, or not reported to TB control programs.

Read More →

How drug-resistant TB can show the path to tackling antimicrobial resistance

Antimicrobial resistance (AMR) is a global health threat, and it is estimated that by 2050, 10 million lives a year and a cumulative US$100 trillion of economic output are at risk due to the rise of drug-resistant infections, if we do not find solutions to tackle the problem.

Read More →

Page 1 of 3 · Total posts: 10

1 2 Last→